An order given by US District Judge William Young in a big-pharma antitrust case has appointed lead counsel to the case, but not without pointing out what he called “unseemly squabble” among the plaintiffs’ firms over who would win that lead. The suit concerns AstraZeneca which, along with three other generic drug makers, drug wholesalers have accused of colluding together to keep AstraZeneca’s heartburn drug Nexium off the sheves. Judge Young appointed the Hagens Berman Sobol Shapiro group to lead the case, but not without harshly commenting on the fight for the lead, in which Grant & Eisenhofer, Garwin Gerstein & Fisher and Berger & Montague also took part. In the words of Judge Young, the fight between the firms was more about who would be awarded the most attorneys’ fees rather than who was best-suited to lead the antitrust case.
Full Content: Thomson Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI